Slide 1: Redefining Immuno-Oncology
NELUX Redefining immuno-Oncology Corporate Presentation June 2024 / Vi J
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections, about Gen
Slide 3: Highlights
Highlights Olvi-Vec: late-stage Clinical Program focused on Platinum Resensitization in Multiple Indications Ongoing pivotal Phase 3 trial in late-stage platinum resistant/refractory ovarian cancer (PRROC) Ongoing Phase 1b/2 trial via systemic in recurrent small cell lung cancer (SCLC) Planned Phase
Slide 4: The Most Advanced Non-local Delivery Oncolytic Immunotherapy
The Most Advanced Non-local Delivery Oncolytic Immunotherapy Olvi-Vec: 7 Completed Clinical Trials (>150 Patients) Physician-preferred routes of delivery "= Regional and Systemic Administration to preferentially locate, colonize and destroy tumor cells, including metastatic disease © IV therapy curr
Slide 5: Program Builds on Completed Trials to Exploit Competitive Advantages
Program Builds on Completed Trials to Exploit Competitive Advantages 3 Upcoming Trial Readouts have Potential to Redefine: Therapy (platinum resensitization in multiple indications) ¥ Modality (systemic administration of an oncolytic virus) Olvi-Vec Anticipated Indication Design Preclinical Phase1 ©
Slide 6: Olvi-Vec Seeks to Unleash Immune System Against Cancer
Olvi-Vec Seeks to Unleash Immune System Against Cancer Key Takeaways Olvi-Vec is being developed as a robust immune modulator that utilizes a triple mode of action to mount a personalized attack against cancer cells throughout the body and aims to: + Selectively replicate in tumors to kill cancer ce
Slide 7: Olvi-Vec-Primed Immunochemotherapy: Reversing Platinum Resistance
Olvi-Vec-Primed Immunochemotherapy: Reversing Platinum Resistance Pro-therapeutic gene expression : . Crom [VIRO-15 Monotherapy Data] i Ehemotherapy synergy: > immunogenic cell death and Positive regulation of T-cell activating - i ‘ presentation of oncogenic neoantigens and trafficking’ > ‘ion of s
Slide 8: A Maturing Modality with Phase Companies Validating OV Potential
A Maturing Modality with Phase 3 Companies Validating OV Potential Limitations of 1st Gen Viruses + Limited to local delivery and scope of addressable cancers AMGEN FDAJEMA approval in Melanoma malignant glioma 9CE Phase 3 monotherapy tral [interim data) in bladder cancer ENELUX > Next Generation .
Slide 9: Regional Administration Program: Ovarian Cancer
Regional —— > Administration ®enevux Program Ovarian Cancer
Slide 10: Ovarian Cancer Program Regional (intraperitoneal) Delivery
Ovarian Cancer Program Regional (intraperitoneal) Delivery Key Takeaways LN + Phase 1 tested condensed dosing schedule and demonstrated tolerability with evidence of anti- tumor activity + Phase 2 demonstrated promising Overall Response Rate (ORR) and Progression Free Survival (PFS), and clinical re
Slide 11: Phase 1b: Anti-tumor Activity as Monotherapy Leading into Combination
hase 1b: Anti-tumor Activity as Monothera Leading into Combination Key Clinical Takeaways IN + Median progression free survival (mPFS) of 6.1 months (median 4 prior lines; 95%CI: 2.2-NA) for the six patients in Cohort 1 virus. monotherapy ~ the dose used in Phase 2. i (-2prior ines)* = PFS: 6.7 mos,
Slide 12: Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy
Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy Heavily Pretreated Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer Data Presentations Interventional Single Group Assignment 1. 2020 Digital Annual Meeting of International n=27 Gynecologic Cancer Society + High-grade
Slide 13: Phase 2 Clinically Meaningful Responses in Heavily Pretreated Patients
Phase 2 Clinically Meaningful Responses in Heavily Pretreated Patients Key Clinical Takeaways IN Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC + All patients had documented progressive disease at enrollment + The mPFS of the patients
Slide 14: Demonstrated Deep and Durable Tumor Shrinkage
Demonstrated Deep and Durable Tumor Shrinkage IN Refractory patients performed as well as resistant patients Key Clinical Takeaways + Overall, 86% of PRROC patients showed tumor reduction, with 91% of platinum-retractory patients showing tumor reduction + Four patients had 100% reduction of target l
Slide 15: Olvi-Vec-Primed Immunochemotherapy Overcomes Refractoriness
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines 15B-01; ‘Stage IIIB papillary serous ECOG:0 BRCA negative PD-Li negative 1SB-15: + Stage IIIB high- grade serous 1SB-17: + Stage l
Slide 16: Durable Survival Benefit
Durable Survival Benefit IN Encouraging mOS and Long- term survival data Key Clinical Takeaways 20% long-term survivors consistent with clinically beneficial immunotherapies + Ona median Sth line of treatment, VIRO-15 Phase 2 patients achieved a mos of 15.7 mos + 4of6 long-term survivors were platin
Slide 17: Seeking to Reset Life Clock of Heavily Pre-treated Patients
Seeking to Reset Life Clock of Heavily Pre-treated Patients While clinical remissions are obtainable, a majority of patients will relapse. » Genelux looks to take an all-comers approach Key Clinical Takeaways “00% sh 0% lnm Olvi-Vec addresses a broad - and underserved pool of 0% “_ ai a | oe Coleen!
Slide 18: Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results
Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance. Primary Endpoint Progression-Free Survival Key Inclusion Criteria Multi-center, randomized open-label" n
Slide 19: Self Launch Olvi-Vec for Ovarian Cancer in the US
Self Launch Olvi-Vec for Ovarian Cancer in the US Drivers of Market Penetration Partnerships Self-Manufacturing Patients Reimbursement Leverage partnership Large-Scale cGMP Underappreciated Compelling Value with GOG Foundation Manufacturing Population Proposition for Payors + Preeminent US-based * C
Slide 20: Systemic Administration Programs: Lung Cancers
Systemic - x> Administration ®enevux Programs Lung Cancers
Slide 21: Systemic Administration Program
Systemic Administration Program Key Takeaways » Ongoing and Planned Clinical Trials + Funding commitment by Newsoara of a5 HOUR neRrad ConeoaeneD autelltn sponser | Thal stes Indeaton cincaistage | Pater® | Rantmatn | stats NSCLC! Re sntiplati Regulate us Se «| (hea 142, 414 snare * Genelux has worl
Slide 22: Systemic Administration Demonstrated Dose-dependent OS Benefit
Systemic Administration Demonstrated Dose-dependent OS Benefit » Dose Escalation Phase 1b Monotherapy Study in Solid Tumors Key Clinical Takeaways Progressed from Last Prior Therapy Demonstrated feasibility and clinical benefit of multiple IV cycles + Median 5 prior lines of therapy * Regimen: vario
Slide 23: Systemic Administration + Chemo Generated Encouraging Data
S stemic Administration + Chemo Generated Encoura Key Clinical Takeaways Anti-tumor effect of IV immunochemotherapy High and Condensed Dosing, IN (single cycle: bolus infusion on 5 consecutive days) Well tolerated: No DIT or MTD reached Anti-tumor effects Virus treatment revitalized tumors to subseq
Slide 24: Phase 2 Trial in Recurrent Non-small Cell Lung Cancer
Phase 2 Trial in Recurrent Non-small Cell Lung Cancer : Patients with Non-small Cell Lung Cancer after First Progression while on Front-Line Immune Checkpoint Inhibitor-based Maintenance Multi-center, randomized open-label n=~142 Primary Endpoint Progression-Free Survival Key Secondary Endpoints Key
Slide 25: Phase 1b/2 Trial in Recurrent Small Cell Lung Cancer
Phase 1b/2 Trial in Recurrent Small Cell Lung Cancer Heavily Pretreated Patients with Platinum-Relapse or Platinum-Refractory Small Cell Lung Cancer Phase 4b Endpoints 4 ae . 7 Primary Endpoint Key Inclusion Criteria Multi-center, randomized open-label =Safety and tolerability =~110 + Prior failure
Slide 26: Industry Collaboration with Newsoara BioPharma Co., Ltd
Industry Collabora n with Newsoara BioPharma Co.,, Ltd ENELUX NEWSGARA > GREhEs Benny Li, PhD Founder and Chief Executive Officer 20+ yrs. global and China local pharma Former VP, GM of Takeda China Development Center and SVP, Executive »& GM of R&D at Hansoh Pharmaceuticals Former Head of Clinical
Slide 27: V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical
V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical VACT Key Trial Takeaways iN V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. established to develop and test V2ACT. V2ACT Immunotherapy, Vaccination increases the numbers of neoantigen-s
Slide 28: Choice Platform Library: 500+ Vectors with 110+ Transgenes
Choice Platform Library: 500+ Vectors with 110+ Transgenes Therapeutic Genes Immune Modularity Therapeutic Antibodies Engineered and selected clonal isolated (non-GMO) viral strains identified from in vitro and in vivo selection criteria Virus-encoded transgenes Cell Growth & Differentiation Regulat
Slide 29: Intellectual Property: Market Exclusivity & Freedom to Operate
Intellectual Property: Market Exclusivity & Freedom to Operate Patent Portfolio: 33 issued patents & 7 pending; [eee fl Olvi-Vec covered by Composition of Matter (2031*) and Manufacturing (2038) St ng IP & a Olvi-Vec: No third-party royalties due Regulatory Designations (© Long Duration of Regulator
Slide 30: Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch
Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch Key Takeaways » Facilities and Operations based in Southern California | Headquarters ‘Westlake AMSA, ~ Large-scale manufacturing process + Capacity for clinical studies and commercial launch needs * Clinical Science capabilities t
Slide 31: Accomplished Leadership Team
Accomplished Leadership Team Executive Team Thomas Zindrick, JD Lourie Zak Paul Scigalla, MD, PhD Chief Executive Officer Chief Financial officer Chief Medical Oficer AMGEN AMGEN Sofizer aeromi DN om, SPNIFL bar Bren PAC Operations & R&D @ Sean Ryder, JD General Counsel ‘HUHELSINN Fmesoblast Board o
Slide 32: Genelux Has Executed on Multiple Milestones and is Positioned for the Future
Genelux Has Executed on Multiple Milestones and is Positioned for the Future Expected Operating Runway into 1Q 2026 — Regular Cadence of Important Program Milestones starting 2H, 2024 Executed Milestones NANA Runway past PRROC topline and rSCLC interim readouts 20+ sites active in Phase 3 Trial in P
Slide 33: Appendix
@HeNeELUx Redefining immuno-Oncology Corporate Presentation | June 2024 \ Appendix \
Slide 34: Accomplished Clinical Advisory Board
Accom lished Clinical Advisory Board Robert Holloway, MD CHAIRMAN Cie vaca cio eniary aan Robert Coleman, MD co-oreter. Synecsogi creslegy. og anata Hogs Prestytsian Albert A. Mendivil, MD Deputy oer of ‘hs Uriveraty of Cineiesi caren Tone Thomas J. Herzog. MD presto ard Neate David M. O'Malley, MD
Slide 35: Olvi-Vec-primed Immunochemotherapy Anti-tumor Activity: CA-125 Biomarker
OWvi-Vec-primed Immunochemotherapy Anti-tumor Activity: CA-125 Biomarker Rapid, Common and Durable Responses CA-125 Decrease ORR by CA-125 © All PRROC Patients: 96% (25/26) © All PRROC Patients: 85% (22/26) © Platinum refractory patients: 85% (11/13) © Platinum refractory patients: 85% (11/13) ae PA
Slide 36: Olvi-Vec-Primed Immunochemotherapy Overcomes Refractoriness
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines Pt.15B-15 (primary platinum-refractory HGSOC) grade serous 1 5000 + EcoG:0 Y ssa of cemo/sevcitumab + BRCA negative tw 4500 po eas
Slide 37: Olvi-Vec Monotherapy Demonstrated Oncolysis and Immune Activation
Olvi-Vec Monotherapy Demonstrated Oncolysis and Immune Activation Data from Phase Ib Monotherapy portion of VIRO-15 trial Key Takeaways » PLATA (PLHSAT) Elimination of Cancer Cels aftr Increased Lymphocyte infiltrationin different cavities Olvi-Vec monotherapy, shows | Eee aay Pleural fluid decrease
Slide 38: CD8+ T-cells: Lymphocytes are Prognostic for Response/Survival
CD8+ T-cells: SUISSE Lymphocytes are Prognostic for Response/Survival / portion of VIRO-15 PtH 15A-16 Data from Phase 1b Monothe! Pre-Olvi-Vec Post-Olvi-Vee ‘prior to subsequent chemotherapy) A ra-tumoral and stromal) are very low in ov cancer, ie, immunol. ‘cold Baseline Screening 146 109 705 | Pos
Slide 39: Long-lasting, Tumor-specific T cell Response Corresponds to Tumor Reduction
Long-lasting, Tumor-specific T cell Response Corresponds to Tumor Reduction Data from Phase 1b Monotherapy portion of VIRO-15 trial IN Key Takeaways Off-the-Shelf Personalized Medicine: Single Agent generates Individualized Results + Olvi-Vec induces favorable & long-lasting Tumor-specific T- cell R
Slide 40: Olvi-Vec: Ideal Backbone for Combination Therapy
Olvi-Vec: Ideal Backbone for Combination Thera Converts Tumor Microenvironment to Inflammatory “Hot Spot” NCT01443260/TUE Study us z gs Induction of acute inflammatory i, cytokines EN (ThI-type related) rf Be VIRO-I5 Study RB. Bo Baseline ‘Massive inflammatory response after (C1024) Baseline W105 w2